Eurofins Viracor BioPharma Expands Bioanalytical Capabilities

February 6, 2026

Lenexa, KS – Eurofins Viracor BioPharma Services, a trusted partner for clinical trial testing services including specialty biomarkers and molecular assays, today announced the expansion of its service offerings to include enhanced bioanalytical testing capabilities compliant with both Good Laboratory Practices (GLP) and Good Clinical Practices (GCP). This expansion strengthens the company’s portfolio of services to enable biopharmaceutical development programs throughout the drug development lifecycle, including pre-clinical, clinical, and post market surveillance.

This advancement follows the relocation and merger of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri to Eurofins Viracor BioPharma’s purpose-built facility occupying eleven acres in Lenexa, Kansas. The bioanalytical organization brings more than 20 years of experience in pharmacokinetics, immunogenicity, and biomarker testing. Combining the two laboratories expands the breadth of services available to the pharmaceutical industry and improves access to integrated technologies, contracting, and scientific expertise - all under one entity.

The new laboratory space in Lenexa was intentionally designed to ensure high-quality handling of patient samples while supporting stringent quality processes, data integrity, and regulatory compliance. With expanded GLP and GCP aligned capabilities, Eurofins Viracor BioPharma now offers a comprehensive suite of bioanalytical services, including method development, validation, and sample analysis, consistent with global regulatory guidance.

By integrating these services within its established clinical trial testing portfolio, Eurofins Viracor BioPharma delivers a more seamless, efficient experience for sponsors- reducing operational complexity and enabling greater consistency across development phases.

This expansion reflects Eurofins Viracor BioPharma’s continued investment in scientific expertise, quality systems, and laboratory infrastructure. It reinforces the company’s commitment to be a trusted partner throughout the increasingly complex drug development process.

Learn more about Eurofins Viracor BioPharma Services’ expanded capabilities and new facility at https://www.eurofins-viracorbiopharma.com/.

For further information:

Jennifer Absher
Director of Marketing
Eurofins Viracor BioPharma
Jennifer.Absher@VBP.Eurofinsus.com
919-744-7884